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Gut dysbiosis contributes to the development of a dysfunctional gut barrier, facilitating the 
translocation of bacteria and inflammagens, and is implicated in colorectal cancer (CRC) pathogenesis. 
Such ‘leaky gut’ conditions result in systemic inflammation, of which a hallmark is increased 
hypercoagulability. Fluorescence antibody confocal microscopy was used to determine circulating levels 
of lipopolysaccharide (LPS) in control and CRC populations. Here we showed that circulating levels of 
LPS are significantly elevated in the CRC population. We also showed that markers of inflammation 
and hypercoagulability are increased in this population. Furthermore, anomalous blood clotting and 
structural changes in blood components are presented. Importantly, the association between LPS 
levels, inflammation, and hematological dysfunction was analysed. Statistical regression models 
were applied to identify markers with strong association with CRC, and to investigate the correlation 
between markers. A core aim is enhanced biomarker discovery for CRC. We conclude that circulating 
LPS can promote systemic inflammation and contribute to the development of a pathological 
coagulation system, with resulting chronic inflammation and an activated coagulation system 
implicated in tumorigenesis. Blood-based screening tools are an emerging research area of interest for 
CRC screening. We propose the use of additional (novel) biomarkers to effectively screen for CRC.
Colorectal cancer (CRC) is the fourth most common cancer-related mortality globally, continuing to affect an 
increasing number of individuals worldwide1–3. Novel strategies must therefore be employed to aid in the iden-
tification of at risk individuals, considering a combination of possible pathogenetic factors4. CRC develops via 
a complex, multistep interaction between specific genetic susceptibilities and external or environmental stress-
ors3,5–7. Hereditary CRCs, such as familial adenomatous polyposis (FAP) and Lynch syndrome, account for less 
than 5% of CRC cases8. Sporadic CRCs are derived from point mutations, affecting the tumour suppressor adeno-
matous polyposis coli (APC) gene (pathway of chromosomal instability)2. This mutation stimulates the formation 
of non-malignant adenomas (polyps), which have the potential for developing into carcinoma. Because the vast 
majority of CRCs are classified as sporadic (constituting 70% of CRC cases), arising from nonhereditary, sponta-
neous somatic mutations2,6,8,9, the influence of environmental factors in the pathogenesis of CRC is an important 
consideration when studying this malignancy.
The intestinal microbiota composition is implicated in CRC development, because it impacts immune, struc-
tural, and metabolic processes10,11. Importantly, changes or disruptions in the composition of the gut microbiota 
(termed ‘dysbiosis’) can contribute to and form part of colorectal tumorigenesis2,12,13. The epithelial cells lining 
the gut are responsible for early immune responses against pathogens through activation of immune signaling 
pathways via innate immune receptor molecules (pattern-recognition receptors (PRRs)), thereby maintaining 
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gut homeostasis10,14,15. For example, PRR Toll-like receptor 4 (TLR4) has the ability to bind lipopolysaccha-
ride (LPS) from Gram-negative bacteria, which initiates downstream signaling and activates the nuclear tran-
scriptional factor kappa B (NF-κB) signaling pathway, consequently inducing other innate immune responses, 
pro-inflammatory gene expression, and recruitment of the adaptive immune system14,15. Bacterial LPS in the 
gut strongly stimulates innate immune signaling, thereby compromising gut homeostasis and normal host 
physiology16.
Patients with inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) have an increased risk 
(10–15%) for developing colitis-associated CRC2,5,6,14. IBD is characterized by a chronic inflammatory state of the 
intestine, and is associated with a changed gut microbiota composition and the presence of an altered intestinal 
permeability14,17. Moreover, chronic inflammation can in turn impact the composition of the gut microbiota 
through metabolic changes, ultimately contributing to a dysbiotic state18. Therefore, disruptions or alterations to 
the normal gut flora affect the host immunity (activate the immune system) and chronic inflammation can con-
tribute to the pathogenesis of CRC2,14,19. Chronic inflammatory disorders induce gene mutations and stimulate 
angiogenesis and cell proliferation20.
Dysbiosis of the gut contributes to the development of a dysfunctional gut barrier, which facilitates bacterial 
translocation from the gut21,22. Of interest here, is bacterial inflammagens that contribute to systemic inflamma-
tion, together with increased hypercoagulability. There is an increased risk of thromboembolic events (hyper-
coagulability) in IBD, because of defective intestinal barrier functions17. Moreover, coagulation dysfunctions 
(deregulated blood coagulation) frequently occur in cancer patients23. Importantly, an activated coagulation sys-
tem is implicated in the pathogenesis of tumour growth and development, with hypercoagulation being present 
in most cancer patients24,25.
Increased intestinal permeability can lead to persistent systemic inflammation, because intestinal bar-
rier dysfunction allows entry of bacterial products into circulation. The presence of low levels of highly potent 
circulating inflammagenic molecules such as LPS, results in an increase in inflammatory molecules such as 
pro-inflammatory cytokines and acute-phase proteins, including serum amyloid A (SAA)26,27. Systemic inflam-
mation affects the hematological system by driving coagulopathies (hypercoagulation is an important hallmark 
of chronic inflammation)28–30. Importantly, anomalous clot formation is characterized by the pathologic assembly 
of fibrin(ogen), containing an amyloid structure26. It has been reported that LPS induces fibrin(ogen) to clot into 
an amyloid form31,32. Circulating bacterial inflammagens and inflammatory molecules, such as SAA, have also 
been shown to generate structural (amyloidogenic) changes in circulating plasma molecules, particularly soluble 
fibrinogen33. This structurally altered conformation in circulating fibrin(ogen) can affect clot formation, thereby 
contributing to hematological pathology.
This paper investigates the presence of circulating LPS and a set of other circulating biomarkers, indicative 
of systemic inflammation, in CRC patients. We show that elevated levels of circulating LPS are correlated with 
dysregulated levels of circulating inflammatory markers. This may, in part, lead to pathological structural changes 
in blood components, including amyloidogenic and hypercoagulated fibrin(ogen), hyperactivity of platelets, and 
morphological changes to erythrocytes (RBCs), all contributing to increased hypercoagulability in CRC patients. 
Therefore, we hypothesize that a bacterial influence, persistent inflammation, hypercoagulation, and colorectal 
carcinogenesis form an intricate relationship. The use of these markers, either alone or in combination, present an 
opportunity for improved CRC blood-based screening.
Methods
Ethical statement. Ethical clearance for the collection of blood samples from healthy individuals and 
patients with newly diagnosed colorectal adenocarcinoma was obtained from the Health Research Ethics 
Committee (HREC) of Stellenbosch University (ethics reference: 6585). All study participants signed an informed 
consent form prior to sample collection. This study, including sample collection and sample processing, was con-
ducted according to the guidelines set by the Declaration of Helsinki.
Study population and sample preparation. Blood samples were collected from 41 healthy individuals 
(16 males and 25 females) with an average age of 51 years, and no history of known inflammatory conditions, 
chronic disease, chronic medication usage or any anti-inflammatory medication, smoking or oral contraceptive 
use in the case of females. Whole blood (WB) from healthy individuals was collected in two sodium citrate tubes 
and a serum separating tube (STT). In addition, blood samples were collected from 26 patients (13 males and 13 
females) with newly diagnosed colorectal cancer (CRC), with an average age of 56 years. The stage of all recruited 
patients was assessed, ranging from 2 to 4, based on histological or imaging tests (CT scans). Of the 26 CRC 
patients, 10 patients had metastases. None of the patients have had any cancer treatment at the time of sample 
collection (no neoadjuvant chemotherapy or radiotherapy). Patients may have smoked, could be on some form 
of chronic medication, with genetic predisposition not forming part of the exclusion criteria. One sodium citrate 
tube and one SST were used for collection of CRC patient WB. Ultrasensitive C-reactive protein (CRP) and lipid 
profile assessment of control and CRC blood samples were performed, using SST, at an accredited Pathology 
Laboratory (PathCare laboratory).
A core aim of this study is biomarker discovery for CRC across a wide range of groups, using WB and platelet 
poor plasma (PPP). WB in sodium citrate tubes was analysed on the same day of collection, but was first left 
to stand at room temperature for at least 30 minutes, before thromboelastography (TEG) of WB and scanning 
electron microscopy (SEM) preparation of WB samples. Citrated WB samples were centrifuged for 15 minutes 
at 3000 × g at room temperature to obtain PPP. The PPP was stored at −80 °C until further sample analyses were 
performed.
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Vascular injury panel analysis. PPP samples from control and CRC subjects were analysed in duplicate 
using the V-PLEX Plus Vascular Injury Panel 2 (human) kit from MSD MULTI-SPOT Assay System (K15198G-1). 
This multiplex kit measures biomarkers that are important in acute inflammation and tissue damage, namely the 
levels of serum amyloid A (SAA), CRP, soluble vascular cell adhesion molecule-1 (sVCAM-1/CD106) and soluble 
intercellular adhesion molecule-1 (sICAM-1/CD54). The 96-well plate (pre-coated with capture antibodies) was 
washed three times with wash buffer, followed by the addition of 25 µL of PPP sample (diluted 1000×), calibrator, 
or control per well, and incubated for two hours at room temperature. Following another wash step, 25 µL of 
detection antibody solution (detection antibodies conjugated with electrochemiluminescent labels) was added to 
each well and incubated for one hour at room temperature. Following the last wash step, read buffer was added to 
each well. Finally, the plate was loaded into the MSD Discovery Workbench 4 instrument, causing the emission 
of light by the captured labels. The instrument measures the intensity of the emitted light, which indicates the 
amount of analyte present in the PPP sample. Biomarker levels are expressed in μg mL−1.
Thromboelastography (TEG) of whole blood (WB) and platelet poor plasma (PPP). 
Thromboelastography (TEG) is a method that is used to measure viscoelastic coagulation parameters. Via stud-
ying the kinetics of clot formation, the coagulation efficiency (clot formation and clot strength) of WB or PPP 
samples can be evaluated. TEG analyses were performed on naïve (unexposed/untreated) WB samples and naïve 
PPP samples, from control subjects and CRC patients. A TEG analysis requires the addition of 340 µL of WB or 
PPP to 20 µL of 0.2 mol L−1 activator calcium chloride (CaCl2) in a disposable TEG cup. The addition of CaCl2 
reverses the effect of the sodium citrate anticoagulant in the collection tube, thereby initiating clotting/coagula-
tion. The samples were placed in a computer-controlled Thromboelastograph 5000 Hemostasis Analyzer System 
for analysis at 37 °C, configured and used according to the manufacturer’s protocol.
Scanning electron microscopy (SEM) analysis of whole blood (WB) smears and platelet poor 
plasma (PPP) clots. Control and CRC WB were prepared for scanning electron microscopy (SEM) anal-
ysis by placing 15 μL directly onto 10 mm round glass cover slips, followed by slightly smearing the blood drop 
across the surface of the cover slip. SEM preparation of CRC WB samples was performed in a dead-air hood 
(with ultraviolet light exposure prior to sample preparation). WB smears were allowed to dry for ±3 minutes 
at room temperature, to allow the cells to adhere to the glass slips. In addition to study the ultrastructure and 
morphology of RBCs and platelets, SEM was also used for the ultrastructural analysis of control and CRC PPP 
clots (to assess and compare fibrin network structure). For fibrin network analysis, 5 μL of thrombin, provided by 
the South African National Blood Service, was added to 10 μL PPP (at 7 U mL−1) on glass cover slips. Thrombin 
activates fibrin polymerisation (converts fibrinogen to fibrin) and creates extensive fibrin fibre networks. All 
cover slips were then placed in 24-well plates. WB smears were subsequently washed in Gibco phosphate-buffered 
saline (PBS) (pH = 7.4) (ThermoFisher Scientific, 11594516) for 15 minutes. PPP clots were immediately sub-
merged in PBS for ±20 minutes. All samples were fixed in 4% paraformaldehyde for a minimum of 30 minutes (to 
crosslink proteins), followed by three PBS wash steps. Samples then underwent secondary fixation with 2–3 drops 
of 1% osmium tetroxide (OsO4) (Sigma-Aldrich, 75632) in double distilled H2O for an additional 15–30 min-
utes. Fixation with OsO4 stabilises membranes and ultrastructural features, enhances contrast, and provides 
conductivity under the scanning electron beam. Following post-fixation, samples were washed three times in 
PBS. The samples were then gradually dehydrated with increasing concentrations of ethanol for 3 minutes each 
(30%, 50%, 70%, 90%, and then three times with 100% ethanol). Sample dehydration was completed with 99.9% 
hexamethyldisilazane (HMDS) ReagentPlus (Sigma-Aldrich, 379212) treatment for 30 minutes. The HMDS was 
removed and replaced with one final drop of HMDS, directly placed onto the samples, after which the samples 
were left to air-dry in a fume hood overnight (±16 hours). Dried samples were mounted on glass microscope 
slides with double-sided carbon tape, and then sputter coated with a thin (±5 nm thick) layer of carbon prior to 
SEM imaging, using a Quorum Q150T coater by performing carbon rod evaporation. This enhances conductivity, 
by preventing build-up of high-voltage charges. SEM ultrastructural analysis of WB smears and PPP clots was 
performed on the Zeiss MERLIN field emission scanning electron microscope, located in the Central Analytical 
Facility (CAF) Electron Microbeam Unit, Stellenbosch University. All micrographs were captured using the 
InLens detector at 1 kV electron beam.
In addition to ultrastructural (qualitative) analysis of PPP clots, changes in fibrin fibre diameter between 
control and CRC PPP clots were quantified. Fibrin networks of ten control samples and ten CRC samples (age- 
and gender-matched) were analysed, captured at 10000x machine magnification. A representative micrograph 
of each sample was selected and a 1 × 1 μm grid (scaled according to the machine magnification) was overlaid 
over these micrographs using ImageJ (FIJI). We analysed 8 × 8 blocks (an area of 8 × 8 μm) and one fibre was 
randomly selected for measurement (in nanometers) per block, which resulted in 64 measurements per micro-
graph. Thick fibres visible as laterally fused fibres were treated as a single fibrin fibre. In cases where a block did 
not contain any visible individual fibres, but only displayed a hypercoagulable dense matted mass, the diagonal 
length of the block (maximum fibre diameter of 248 nm) was allocated. This systematic approach ensured that 
the fibres were measured in an unbiased manner, and that a variety of different fibres in the selected area was 
included for measurement. Micrographs were enlarged to an extent in order to easily measure the diameters of 
thin fibres. Frequency histograms were constructed in GraphPad Prism 7.04, to graphically display fibre diameter 
distribution. Moreover, the average fibrin fibre diameter, maximum fibrin fibre diameter, and minimum fibrin 
fibre diameter of the ten control samples and ten CRC samples were noted.
Immunostaining of platelet poor plasma (PPP) smears. PPP (5 µL) from healthy subjects and CRC 
patients was smeared on a microscope slide, after which the slide was air dried for ±45 minutes. The sample was 
then fixed with 10% neutral buffered formalin (NBF) for 3–5 minutes. Following three PBS washes, the sample 
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was blocked with 5% goat serum (prepared in PBS) for 30 minutes, after which it was stained with primary anti-
body (made up in 5% goat serum in 1:200), Anti-E. coli LPS antibody [2D7/1] (mouse monoclonal IgG, ab35654, 
Abcam), for one hour at room temperature. This primary antibody was used as a proxy to measure the levels of 
the Gram-negative membrane component LPS. Lipid A is a highly conserved diglucosamine-based phospho-
lipid34, and the lipid A moiety synthesized by most Gram-negative bacteria is similar to (or resembles) the lipid 
A molecule of E. coli35,36. Following three PBS washes, the sample was stained with secondary antibody (made 
up in PBS in 1:200), Goat Anti-Mouse IgG H&L (Alexa Fluor 488) (ab150113, Abcam), for one hour at room 
temperature in the dark. Finally, following the last wash step, a cover slip was mounted with a drop of Dako flu-
orescence mounting medium for confocal analysis. Prepared PPP smears were stored at −20 °C (protected from 
light), and viewed using a Zeiss LSM 780 with ELYRA PS1 confocal microscope with a Plan-Apochromat 63×/1.4 
Oil DIC M27 objective. A 488 nm Argon excitation laser was used, with emission measured at 493–630 nm. Gain 
settings were kept constant for data acquisition, to permit accurate statistical analyses. Of each prepared PPP 
smear, 4–8 micrographs were captured, as well as from secondary antibody controls. Non-stained controls were 
also included. Of 29 control PPP smears, 145 images were acquired, and 154 images from 25 CRC PPP smears. 
The mean fluorescence intensity (MFI) from all acquired images was computed (using ImageJ (FIJI)37), followed 
by dividing the MFI of each image by the average MFI of the corresponding secondary antibody control images, 
resulting in normalised fluorescence intensity values per control or CRC sample. In this manner, by accounting 
for non-specific secondary antibody binding, anti-E. coli LPS antibody binding could be accurately quantified.
Confocal analysis of platelet poor plasma (PPP) clots. In order to investigate the fluorescence 
(anomalous) amyloid signal present in control and CRC PPP clots, PPP samples were incubated with the 
amyloid-selective Amytracker 630 marker (Ebba Biotech AB). Control and CRC PPP were prepared for confocal 
analysis by adding 2 µL of the fluorescent amyloid marker (of the working solution, made up by diluting the stock 
concentration in PBS at a 1:20 ratio) into 96 μL PPP. Following the addition of Amytracker 630, it was incubated 
in the plasma for 30 minutes (protected from light) at room temperature. In addition, unstained PPP of healthy 
individuals and CRC patients was also included for analysis, to investigate the presence of autofluorescence signal 
in unstained control and CRC PPP clots. After incubation time (for stained samples), PPP clots were created by 
transferring a small volume (10 µL) of the stained (or unstained) PPP sample to a microscope slide, after which 
thrombin at 7 U mL−1 was added in a 1:2 ratio (5 µL thrombin: 10 µL PPP), to create extensive fibrin fibre net-
works. A cover slip was placed over the prepared clot, and control and CRC clots were viewed using a Zeiss LSM 
780 with ELYRA PS1 confocal microscope with a Plan-Apochromat 63×/1.4 Oil DIC M27 objective. A 488 nm 
Argon excitation laser was used, with emission measured at 579–695 nm. For data acquisition and comparison 
between control and CRC clot images, gain settings were kept constant to ensure a reliable statistical outcome. All 
micrographs of the prepared clots were captured in an unbiased manner as 3 × 3 tile images, with 3–5 tiles cap-
tured per sample. The MFI from all acquired PPP clot images was computed (using ImageJ (FIJI)) to compare the 
response to the Amytracker 630 stain in control and CRC populations, as well as for comparing unstained clots.
Statistical analysis. To determine the strength of associations between biomarkers and CRC, logistic and 
ordinal regression were performed. Three models were compared: model 1 uses unadjusted logistic regression, 
model 2 adjusts for age and gender, and model 3 considers an ordinal relationship between the biomarkers and 
CRC stage (ranging from 2 to 4). The adjustment addresses the small differences between the control and CRC 
age and gender distribution – removing these possible confounding factors. Ordinal regression was performed 
to investigate the strength of the association between biomarker levels and the stage of CRC (i.e. disease progres-
sion). Furthermore, linear regression was also performed to determine the correlation between selected param-
eters. Statistical significance was accepted at p < 0.002 (with level adjusted based on Bonferroni correction). This 
statistical analysis was performed using R version 3.6.1 using the stats and ordinal packages. GraphPad Prism 
7.04 was also used to prepare image plots and perform the corresponding unpaired t-tests or Mann-Whitney 
non-parametric tests.
Results
Systemic inflammation, altered lipid metabolism, and vascular dysfunction. Table 1 shows the 
sample demographics, Pathology Laboratory results, as well as the V-PLEX Plus Vascular Injury Panel 2 (human) 
kit results of both populations. The significantly higher ultrasensitive CRP levels in CRC patients, compared to 
age-matched controls, illustrate the presence of active infection/inflammation in these patients. The logistic and 
ordinal regression models indicated that this parameter is statistically significant, being predictive of an increased 
chance of CRC and also correlating to the stage of CRC. PPP samples from healthy individuals and CRC patients 
were analysed for specific inflammatory biomarkers, using the vascular injury panel kit. It is known that the 
non-specific hepatic inflammatory markers CRP and SAA are persistently elevated during chronic inflammation, 
as a result of infectious stimuli or trauma38. CRP plasma levels can increase from ±1 μg mL−1 to over 500 μg mL−1 
within 24–72 hours of severe tissue damage, including those caused by trauma and progressive cancer39. CRP 
levels are significantly increased in CRC patients, indicative of local inflammation, also acting as marker during 
a systemic inflammatory response40,41. Both the logistic and ordinal regression models identified this parame-
ter as statistically significant, suggesting that CRP levels are associated with CRC and correlates to CRC stage/
progression. The serum/plasma SAA concentration in healthy individuals range from 1–5 μg mL−1. However, 
under pathological conditions, including inflammatory or infectious diseases, as well as neoplasia, serum SAA 
concentrations >10 μg mL−1, and up to 1 mg mL−1 can be found42. The SAA levels are also significantly elevated 
in CRC patients, with SAA identified as a significant parameter across all models. Moreover, CRC patients show 
significantly upregulated levels of the pro-thrombotic mediator sICAM-1, as observed in a variety of inflamma-
tory conditions43. Healthy sICAM-1 serum concentrations have been reported to range between 0.1 μg mL−1 and 
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0.408 μg mL−1 44. This parameter is identified as significant across all models, but there is not a significant differ-
ence in sVCAM-1 levels between control and CRC populations.
Inflammation and infections result in abnormalities in lipid metabolism, classically associated with elevated 
levels of serum total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and decreased levels 
of serum high-density lipoprotein (HDL) cholesterol45. CRC patients have significantly decreased serum total 
cholesterol and HDL cholesterol levels, compared to healthy individuals. These parameters are identified as sig-
nificant across all models. However, LDL cholesterol levels, non-HDL cholesterol levels, and triglyceride levels are 
not predictive of an increased chance of CRC (or associated with CRC stage). When adjusting for age and gender, 
some markers showed a stronger association with CRC. For example, after adjustment for age and gender, there is 
stronger association between a decrease in HDL cholesterol levels and the odds of CRC. The lipid profile of CRC 
patients illustrates an altered lipid metabolism, but not hyperlipidaemia. Moreover, the total cholesterol/HDL 
cholesterol ratio, an indicator of cardiovascular disease (CVD) risk, is identified as a significant parameter by 
logistic regression (when adjusted for age and gender) and ordinal regression models. In summary, CRC patients 
demonstrate a dysregulated lipid metabolism, together with a pro-inflammatory and pro-thrombotic state.
Hypercoagulability and pathological structural changes in blood components. The hematolog-
ical system is sensitive and highly responsive to dysregulated (upregulated) circulating inflammatory molecules, 
which affect the morphology, ultrastructure, and function of platelets, RBCs, and fibrin(ogen), all influencing 
(hyper)coagulability. Clotting parameters, as measured by TEG, indicate to what degree the coagulation sys-
tem is activated (or pathological) over time. The results of the TEG analysis of CRC WB are shown in Table 2. 
No significant difference was observed in the clot initiation time/reaction time (R value) between controls and 
CRC patients. However, compared to healthy individuals, CRC patients showed a significantly decreased time 
(or increased rate) to achieve a certain level of clot strength (amplitude of 20 mm), indicated by kinetics (K 
Demographics
Healthy individuals CRC patients
Gender Male (n = 16), Female (n = 25) Male (n = 13), Female (n = 13)
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Table 1. Demographics, Pathology Laboratory results, and vascular injury panel results of healthy individuals 
and colorectal cancer (CRC) patients. Data expressed as median and [25−75% quartile range]. Significant 
differences are shown in bold for all models. All CRC patients with hypertension used medication for blood 
pressure regulation. Prescribed medication was recorded, and included Enalapril, Ridaq, Atenolol, Amlodipine, 
LASIX (furosemide), Losartan, and Perindopril.
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value). CRC patients also had significantly higher TEG values for the clot angle (reflecting the rate of fibrin 
fibre cross-linking or clot formation/thrombin burst), as well as for the maximum amplitude (MA) (maximum 
strength/rigidity/stiffness of the clot). Moreover, the maximum velocity of clot growth (MRTG) and total clot 
strength (TTG) were significantly increased in CRC patients. However, there was not a significant difference in 
the time from clot initiation to maximum velocity of clot growth (TMRTG) between controls and CRC patients. 
Specifically, changes in MRTG and TTG reflect changed or abnormal polymerization of the soluble plasma pro-
tein fibrinogen to insoluble fibrin fibres46. The other coagulation or clotting parameters are indicative of the 
interactions between all blood components, including cells and plasma proteins, influencing coagulation46. In 
summary, of the seven viscoelastic parameters used to assess coagulation efficiency, five coagulation parameters 
differed significantly between healthy controls and CRC patients. Both the logistic and ordinal regression models 
identified these parameters as significant, having a strong association with (predictive of an increased chance of) 
CRC and also correlates to CRC stage. The two TEG WB clot parameters that did not illustrate a clinical signif-
icance are related to clot initiation time (R value) and time taken to achieve maximum velocity of clot growth 
(TMRTG). However, once initiated, a clot of increased strength forms faster. Together, these differences suggest 
an increased clotting potential of WB from CRC patients, compared to WB of healthy individuals. Fig. 1 shows 
box and whisker plots of the four inflammatory biomarkers of the vascular injury panel, HDL cholesterol and 
LDL cholesterol levels, as well as the two most significant TEG WB clot parameters (MRTG and Angle).
Representative SEM micrographs of WB smears from healthy individuals and CRC patients are shown in 
Fig. 2. Healthy RBCs illustrate a typical discoid shape, whereas RBCs from CRC patients display atypical/abnor-
mal non-discoid shapes, with increased number of eryptotic RBCs. Furthermore, healthy RBC membranes pres-
ent smooth membrane surfaces, while CRC patients display pathological changes to RBC membrane structure. 
RBC dysfunction may potentially lead to anaemic conditions in CRC patients. RBC aggregates appear frequently 
in WB smears from CRC patients. Platelets from healthy individuals have a small and round appearance, only 
slightly activated (displaying pseudopodia formation), due to contact activation during sample preparation. 
However, an increased level of platelet activation, membrane spreading, as well as platelet-derived microparticle 
formation are present in WB smears from CRC patients. Platelet aggregates or platelet clumping are also abun-
dantly present in CRC WB. Importantly, the aim here was not to indicate differences in samples from patients 
with different stages of CRC, but to compare SEM micrographs of WB smears from healthy individuals to that 
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Table 2. Results of the seven viscoelastic thromboelastography (TEG) clot parameters assessing (hyper)
coagulability of whole blood (WB) and platelet poor plasma (PPP) samples from healthy individuals and 
colorectal cancer (CRC) patients. Data expressed as median and [25−75% quartile range]. Significant 
differences are shown in bold for all models.
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from CRC patients as a group (ranging from stage 2 to 4). All CRC patients, independent of the stage, demon-
strate comparable pathological changes to the morphology and ultrastructure of blood cells, because all CRC 
patients are burdened with systemic inflammation. An activated coagulation system is a hallmark of persistent 
inflammation. SEM micrographs of WB smears from all CRC patients therefore show similar pathological fea-
tures, indicative of increased hypercoagulability.
Representative SEM micrographs of WB smears from only stage 4 CRC patients are shown in Fig. 3, focusing 
on the interactions between different blood components (platelets, RBCs, leukocytes, and possibly cancer cells). 
It is known that circulating tumour cells (CTCs) can have different sizes (have a large heterogeneity), but most 
have large sizes47. However, CTCs may also have similar sizes than leukocytes. It is therefore difficult to identify 
cancer cells in the presence of other blood components with SEM analysis. However, Fig. 3 illustrates abundant 
agglutination between various cellular entities in stage 4 CRC patients, which may influence hypercoagulability.
Similar significant differences were observed when comparing the kinetic changes of CRC PPP to that of 
healthy controls, as seen with TEG analysis of CRC WB (refer to Table 2). Four coagulation parameters out of 
the seven viscoelastic TEG clot parameters were identified as significant across all models. The changes observed 
in TEG PPP clot parameters, mainly affected by fibrin(ogen), suggest that the rate of clot formation and clot 
strength are increased in CRC patients. Importantly, clot ultrastructure (an important way to measure hema-
tological healthiness) of healthy PPP clots and CRC PPP clots can be assessed via SEM analysis, which may 
convey important visual information regarding changes in fibrin packaging, involved in the clotting process48. 
Fig. 4 shows representative SEM micrographs, indicating the structural differences between fibrin fibre networks 
from healthy clots and CRC clots. Clot structure of healthy PPP (with added thrombin) appears as looser fibrin 
networks, with more open spaces visible between branching fibres. It is typical of healthy fibrin clots to form a 
net where individual fibrin fibres are distinguishable. However, PPP from CRC patients, with added thrombin, 
Figure 1. Box and whisker plots of the four vascular injury panel biomarkers (μg mL−1), HDL cholesterol 
and LDL cholesterol levels (mmol L−1), and the TEG WB clot parameters MRTG (Dyn cm−2 s−1) and Angle 
(degrees) for healthy individuals (left box) and colorectal cancer (CRC) patients (right box).
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appears as a meshed network (or dense matted deposits). Thicker fibres are fused together, and cannot always be 
distinguished. When thick/dense plates are observed, it is an indication of hypercoagulability.
In Fig. 5, a 1 × 1 μm grid is overlaid on micrographs of representative fibrin clots of the control group and CRC 
patient group (with the 8 × 8 μm areas indicated by the black squares), where white arrows indicate examples of 
fibres that were selected for diameter measurement. Histograms of the frequency distributions of fibre diameters 
of the control group and CRC patients are shown on Fig. 6. The single largest and smallest measurement of each 
healthy individual were compared to the single largest and smallest measurement of each CRC patient. Similarly, 
the average fibre diameter of each healthy individual was compared to the average fibre diameter of each CRC 
Figure 2. Representative scanning electron micrographs of whole blood (WB) smears, focusing on 
erythrocytes (RBCs) and platelets of healthy individuals and colorectal cancer (CRC) patients.
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patient (refer to Table 3). It is clear from Fig. 6 that healthy fibrin fibres have smaller diameters, distributed 
between a range of 60–360 nm. On the other hand, fibrin fibres in CRC PPP clots have a more compact distribu-
tion (over larger fibrin diameters), which results in higher counts of larger diameters. The average, maximum, 
and minimum diameters of fibrin fibres in clots created from CRC PPP are significantly higher than that from 
healthy PPP.
Figure 3. Representative scanning electron micrographs of whole blood (WB) smears of stage 4 colorectal 
cancer (CRC) patients, focusing on different cellular interactions. White arrows indicate hyperactivated 
platelets, eryptotic erythrocytes (RBCs), leukocytes, and possible circulating tumour cells (CTCs). Micrographs 
in the second column are higher magnification (zoomed-in) micrographs of the areas indicated with black 
boxes in the first column.
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Bacterial lipopolysaccharide (LPS) in the circulation of CRC patients. A direct fluorescence LPS 
antibody-based technique was employed to determine the circulating levels of LPS in CRC patients, compared to 
that of healthy individuals. This technique has been optimized previously27. Representative confocal micrographs 
of PPP smears with added anti-E. coli LPS antibody and secondary antibody, from healthy individuals and CRC 
patients, are shown in Fig. 7A. Table 4 shows the normalised MFIs of the confocal images of PPP smears. There is 
a significant increase (at Bonferroni corrected levels) in the fluorescence LPS signal in PPP from CRC patients, in 
comparison with healthy PPP (refer to Fig. 7B for a box and whisker plot of the normalised MFIs of the confocal 
micrographs of healthy and CRC PPP smears). The fluorescence LPS signal was identified as a parameter with 
statistical significance by logistic regression modelling, with elevated circulating LPS levels being predictive of an 
increased chance of CRC (refer to Table 4).
Given the significantly elevated levels of LPS present in CRC PPP over healthy PPP, the correlation between 
LPS and other markers investigated in this paper, was calculated. Refer to Fig. 8 for a lattice of parameter 
cross-plots, where the upper diagonal shows the correlation coefficients and the lower diagonal shows pairwise 
scatter plots coloured by disease stage (green represents the control population, orange represents stage 2 CRC 
patients, and red represents stage 3 and 4 CRC patients). Linear regression between biomarkers (across a wide 
range of groups) and the fluorescence LPS signal firstly demonstrated that a significant correlation exists between 
LPS and TEG WB parameters (as shown in the cross-plot). The adjusted R2 values of 0.28 for MRTG and 0.16 
Figure 4. Representative scanning electron micrographs of fibrin clots from healthy individuals and colorectal 
cancer (CRC) patients, where thrombin was added to platelet poor plasma (PPP) to create extensive fibrin 
networks. Micrographs were enhanced for publication clarity, by adjusting the brightness and contrast of the 
images in Adobe Photoshop CS6.
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for Angle are indicative of a positive relationship between a pathological coagulation system (hypercoagulabil-
ity) and the presence of circulating LPS. CRP also correlates to LPS presence (R2 value of 0.15). Moreover, the 
pro-thrombotic mediators (or vascular damage markers) sICAM-1 and sVCAM-1 (R2 values of 0.12 and 0.11, 
respectively) also correlate with LPS levels, although not as strongly as the three TEG WB parameters and CRP.
Aberrant blood clots and misfolded fibrin(ogen). The presence of very low concentrations of LPS 
induces a change in the nature or structure of fibrin(ogen) by causing fibrin(ogen) plasma proteins to clot into an 
amyloid form31,32. Fibrinogen mainly consists of α-helices, but when amyloidogenesis occurs, fibrinogen under-
goes a secondary structural change during polymerisation to fibrin32. PPP was incubated with the luminescent 
conjugated oligothiophene dye Amytracker 630, followed by the addition of thrombin to create a clot. Aberrant 
blood clots (anomalous clot formation) can be characterized by the binding of amyloid-selective stains, includ-
ing Amytracker 630. Therefore, differences in protein structure and nature, specifically the presence of amyloid 
Figure 5. Scanning electron micrographs (overlaid with a 1 × 1 μm grid) of fibrin clots from a healthy 
individual and colorectal cancer (CRC) patient, where thrombin was added to platelet poor plasma (PPP) 
to create extensive fibrin networks. Arrows indicate examples of fibres selected for measurement in blocks. 
Micrographs were enhanced for publication clarity, by adjusting the brightness and contrast of the images in 
Adobe Photoshop CS6.
Figure 6. Histograms illustrating the frequency distributions of the fibrin fibre diameters of fibrin clots from 
(A) healthy individuals (n = 10) and (B) colorectal cancer (CRC) patients (n = 10).
Fibrin fibre 
diameter (nm) Control group CRC group Significance
Average 158.9 [145.3–176.3] 339.8 [311.2–351.8] ****
Maximum 332.4 [295.5–353.1] 1418 [1256–1418] ****
Minimum 81 [68.77–93.36] 110.7 [98.73–150.8] ***
Table 3. Analysis of fibrin fibre diameters of healthy individuals (n = 10) and colorectal cancer (CRC) patients 
(n = 10), with the corresponding significance (***p < 0.001; ****p < 0.0001). Data expressed as median and 
[25–75% quartile range].
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structures in PPP clots (an indication of pathological clotting) of CRC patients were compared to that of healthy 
individuals. MFIs were used to reflect the fluorescence (anomalous) amyloid signal. Representative confocal 
micrographs of clots prepared from stained PPP of healthy individuals versus clots prepared from stained PPP 
Figure 7. (A) Representative platelet poor plasma (PPP) smears with added anti-E. coli LPS antibody and 
secondary antibody, from healthy individuals and colorectal cancer (CRC) patients. Micrographs were 
enhanced for publication clarity, by adjusting the brightness and contrast of the images in Adobe Photoshop 
CS6. (B) Box and whisker plot of the normalised (to secondary antibody control signal) mean fluorescence 
intensities (MFIs) of healthy (n = 29) (left box) and CRC (n = 25) (right box) PPP smears, with added anti-E. 
coli LPS antibody and secondary antibody.
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of CRC patients are shown in Fig. 9A. The MFIs of the control and CRC clot images were compared in a box and 
whisker plot, showing that the fluorescence signal in stained PPP clots from CRC patients is increased (Fig. 10A). 
Logistic regression modelling identified Amytracker 630 signal as a statistically significant parameter, but with 
smaller effect size than the fluorescence LPS signal (also refer to Table 4).
Moreover, in order to account for the effect of autofluorescence (a validation step), unstained PPP clots of 
healthy individuals were compared to unstained PPP clots of CRC patients. There is no significant difference in 
the autofluorescence signal (without the use of any fluorescent stain) of PPP clots from CRC patients, compared 
to PPP clots from healthy individuals (refer to Table 4 and to Fig. 10B for a box and whisker plot). This suggests 
that the fluorescence changes observed in the stained samples are not confounded by the presence of autoflu-
orescence (intrinsic fluorescence) of these clots. Representative confocal micrographs of clots prepared from 
Healthy individuals CRC patients Unadjusted OR (99.8% CI) Adjusted OR (99.8% CI)
Anti-E. coli LPS 
antibody 0.52 [0.25–0.95] 1.22 [0.71–2.93] 2.2764 (1.5094–3.808) 2.1253 (1.372–3.6713)
Amytracker 630 2.65 [2.16–2.97] 3.01 [2.58–4.02] 2.6934 (1.3689–6.7481) 2.5903 (1.3436–6.4636)
Unstained 1.55 [1.47–1.65] 1.51 [1.4–1.64] 1.4756 (0.13654–20.532) 1.7687 (0.13305–30.73)
Table 4. Normalised mean fluorescence intensities (MFIs) of confocal images of platelet poor plasma (PPP) 
smears with added anti-E. coli LPS antibody and secondary antibody, and MFIs (units are unscaled pixel 
intensity (0 to 255)) of confocal images of PPP clots (stained with Amytracker 630 and unstained). Data 
expressed as median and [25−75% quartile range]. Significant differences are shown in bold for both models.
Figure 8. Lattice of cross-plots of selected biomarkers for colorectal cancer (CRC) across a wide range of 
groups, where the upper diagonal shows correlation coefficients (green = control population; orange = stage 2 
CRC patients; red = stage 3 and stage 4 CRC patients).
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unstained PPP of healthy individuals versus clots prepared from unstained PPP of CRC patients are shown in 
Fig. 9B. Interestingly, the lattice of parameter cross-plots (Fig. 8) indicates that Amytracker 630 signal strongly 
correlates to the fluorescence LPS signal (adjusted R2 value of 0.36).
Discussion
Our results are diagrammatically represented in Fig. 11 and the following paragraphs describe the relevant find-
ings. We analysed and compared CRC patient blood samples to that of healthy controls in order to identify (dis-
cover) biomarkers/parameters that correlate to CRC status (to determine the strength of associations between 
biomarkers and CRC, and investigate their correlation to CRC stage/progression). This research aim could be 
achieved by employing logistic and ordinal regression, using healthy control and CRC data. It would fall outside 
the scope of this specific study to include blood samples from individuals with colorectal polyps as additional 
control samples, because it would not have had a significant impact on our approach in addressing our original 
research aim. Furthermore, we did not compare CRC cases to (chronic) inflammation cases, because our research 
aim could be achieved by comparing data of only CRC cases to healthy controls. Patients with Crohn’s disease or 
ulcerative colitis are at risk of developing colitis-associated cancer (CAC)49. This is a classical inflammation-driven 
or so-called “inflammation-induced” CRC49. Therefore, even though chronic inflammation acts as a preceding 
event that can lead to CRC, inclusion of such cases would not have added to achieving our original research aim.
We showed that the fluorescence E. coli LPS signal is significantly higher in PPP from CRC patients, com-
pared to PPP from healthy individuals. Moreover, we found that there is a relationship or correlation between 
the presence of circulating LPS and CRP levels. This suggests that LPS is, to some degree, associated with the 
pro-inflammatory status observed in these patients. Infection, inflammation, and tissue injury lead to the pro-
duction of CRP50, a widely used (non-specific) inflammatory marker26. SAA levels in the blood are also elevated 
in cases of trauma, infection, and inflammation51, acting as modulator and clinical marker of active inflamma-
tion14,51. Importantly, SAA can be upregulated up to 1000-fold in response to neoplasia51, and predicts a poor 
prognosis52. It has been reported that SAA, in comparison with other acute-phase proteins such as CRP, may 
serve as a more reliable, specific, and sensitive inflammatory biomarker38,53, also of disease activity in colorectal 
carcinoma54. The combination of elevated CRP and SAA levels, as seen in our CRC population, may be indicative 
of an increased risk of CRC38. Ordinal regression modelling also indicated that CRP and SAA levels have strong 
associations with CRC stage/progression. Importantly, as shown in the parameter cross-plot (Fig. 8), there exists 
a strong correlation between these two parameters.
Figure 9. (A) Representative confocal micrographs of clots prepared from platelet poor plasma (PPP) stained 
with the amyloid-selective Amytracker 630 marker, showing the fluorescence (anomalous) amyloid signal of 
healthy individuals and colorectal cancer (CRC) patients. (B) Representative confocal micrographs of clots 
prepared from unstained PPP, showing the autofluorescence signal of healthy individuals and CRC patients. 
Micrographs were enhanced for publication clarity, by converting images to grayscale, followed by adjusting the 
brightness and contrast of the images in Adobe Photoshop CS6.
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It is important to note here that, in addition to acute-phase proteins, elevations in pro-inflammatory cytokines 
(such as interleukin-12 (IL-12) and interferon-γ (IFN-γ)) and cell populations are also representative markers of 
inflammation. It is known that the overexpression of T helper 17 (Th17) cells is implicated in tumorigenesis and 
associated with a poor prognosis55, whereas elevated expression of the Th1 cluster is associated with a better prog-
nosis in CRC56. Furthermore, M1 macrophages, which are tumour associated macrophages (TAMs) with tumour 
preventing properties, have been shown to be associated with improved survival in CRC57.
SAA can activate the transcription factor NF-κB58, which plays important roles in regulating thrombosis59. 
SAA induces the expression of pro-thrombotic mediators, including sICAM-1 and sVCAM-126. Ordinal regres-
sion modelling indicated that sICAM-1 levels correlate to the stage of CRC. It has been reported that sICAM-1 
is associated with cancer progression, with sICAM-1 levels being indicative of the prognosis of CRC patients60. 
Furthermore, the significantly elevated ultrasensitive CRP levels in CRC patients are indicative of an increased 
risk for cardiovascular events and peripheral vascular disease61. Chronic inflammatory diseases, including CRC, 
are associated with an increased risk for atherosclerosis and ultimately cardiovascular disease45,62.
Long-term inflammation acts as an important hallmark of CRC63, and its role in tumour initiation, promotion, 
and progression is well-established64. Chronic systemic inflammation therefore forms a major part of CRC tum-
origenesis65–67. Moreover, cross-talk exists between lipid metabolism and chronic inflammation. Dyslipidaemias, 
classically defined as decreased concentrations of circulating HDL cholesterol and elevated concentrations of 
triglycerides (hypertriglyceridemia)68, go hand in hand with chronic low-grade inflammation and infections69,70. 
CRC patients demonstrated significantly decreased HDL cholesterol levels, but none of the models have identified 
triglyceride as a statistically significant parameter. A study by Zhang and co-workers found that the serum levels 
of total cholesterol and LDL cholesterol in CRC patients were significantly lower than in healthy individuals, but 
no statistically significant difference in the serum levels of triglycerides between the two groups71. We also found 
that serum total cholesterol levels are significantly decreased in CRC patients, which correlates to increased CRC 
risk72. In line with this, ordinal regression modelling illustrated that total cholesterol levels are predictive of the 
stage or level of CRC. Abnormal lipid levels correlate to CRC risk68, but the role of cholesterol in carcinogenesis 
remains conflicting73.
A pro-inflammatory profile and coagulopathies such as a hypercoagulable state (pathological clotting) are 
linked29,46. Systemic (and localized) inflammatory processes can activate the coagulation system, causing systemic 
hypercoagulability17. The analysis of the viscoelastic clot parameters of CRC WB and PPP, as measured by TEG, 
Figure 10. Box and whisker plots showing the distribution of the mean fluorescence intensities (MFIs) of (A) 
stained healthy (n = 10) (left box) and colorectal cancer (CRC) (n = 26) (right box) platelet poor plasma (PPP) 
clots and (B) unstained healthy (n = 10) (left box) and CRC (n = 26) (right box) PPP clots.
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is an effective approach to assess (hyper)coagulability (the efficiency of coagulation). TEG results indicated that 
WB and PPP samples from CRC patients have an increased tendency to develop a larger and denser clot quicker 
versus WB and PPP samples from healthy controls. Importantly, a significant positive correlation exists between 
LPS and markers of an activated or pathological coagulation system (TEG WB clot parameters). This suggests that 
coagulation dysfunctions may predict the presence of LPS and vice versa.
SEM analysis of WB smears conveyed valuable insights in the assessment of (hyper)coagulability. Distinct 
patho-morphological changes in the ultrastructure of platelets and RBCs, together with the increased aggluti-
nation between different cells, may add to the increased hypercoagulability in CRC patients, depicted by WB 
TEG results. The atypical non-discoid shapes of RBCs from CRC patients suggest RBC dysfunction, which may 
potentially lead to anaemic conditions. Anaemic conditions can be classified in different ways, of which one is 
based on the morphology or size of RBCs74. Furthermore, an increased number of eryptotic RBCs are present in 
CRC WB, which may lead or contribute to the development of anaemia75,76. It has been reported that anaemia 
serves as a sign of CRC77, and that cancer-associated anaemia is considered as a prognostic factor of the survival 
of cancer patients75.
Fibrin clot structure was also assessed with SEM analysis. As mentioned, fibrin(ogen) is the main deter-
minant in PPP hypercoagulability, and SEM analysis of CRC fibrin clots confirmed an altered fibrin network 
Figure 11. Summary of the results of the paper, highlighting circulating lipopolysaccharide (LPS) as one of 
the main factors promoting systemic inflammation and hematological dysfunction in colorectal cancer (CRC) 
patients. Figure made in ©BioRender - https://biorender.com/.
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ultrastructure, compared to healthy fibrin clots. It is clear form Fig. 6 and Table 3 that the diameters of fibrin 
fibres in clots created from CRC PPP are increased, compared to those of control PPP clots. CRC patients have a 
much larger amount of thick fibre counts than the control group, with thinner fibres appearing seldom. The dense 
matted surfaces observed in CRC fibrin clots are thus formed by thicker fibers, appearing as uniform plates, hence 
resulting in a hypercoagulable state (as suggested by PPP TEG results). The abnormal viscoelastic clot parameters 
measured by WB and PPP TEG analysis, as well as SEM analysis of WB smears and fibrin clot structure, sug-
gest that blood components react to and undergo certain pathological changes in the presence of a dysregulated 
inflammatory milieu, ultimately affecting clot formation, causing clot hypercoagulability or an increased clotting 
potential. Circulating inflammatory markers therefore have the potential to change and activate the coagulation 
system, thereby promoting hematological pathology. It is known that malignancy leads to hypercoagulability, 
which forms part of tumorigenesis and metastasis via promoting angiogenesis25,66. An intricate relationship (bidi-
rectional association) therefore exists between pathological hemostatic system activation and cancer23,66.
The anomalous (amyloidogenic) clotting of blood has been implicated in forming part of the origin of hyper-
coagulability in a variety of chronic inflammatory diseases31,78. Circulating LPS can induce the formation of 
anomalous or misfolded circulating fibrin(ogen), characterized by amyloid formation in fibrin(ogen), with the 
addition of thrombin (when forming a clot)31,32. We showed that CRC PPP clots contain significantly greater 
(anomalous) amyloid-specific signal than control PPP clots, by using the amyloid-selective Amytracker 630 
marker. It has also been reported that LPS is closely associated with dense matted (amyloid) fibrin(ogen) depos-
its, which highlights the important role that LPS may play in abnormal blood clotting or hypercoagulation27. 
The strong correlation between Amytracker 630 signal and LPS presence further motivates that LPS may play an 
important role in anomalous clot formation in CRC patients. Evidence is therefore presented that elevated levels 
of circulating LPS, dysregulated levels of circulating inflammatory markers, and a pro-coagulant state are asso-
ciated with CRC. We suggest that the statistically significant parameters identified in this study can be used for 
CRC screening, because logistic and ordinal regression models indicated that these biomarkers are predictive of 
an increased chance of CRC and correlate to the stage of CRC. However, the relatively small sample size is a limit-
ing factor of this study, which necessitates future research with larger sample populations. Additionally, different 
subgroups of patients should be identified in future studies. For example, CRC cases and (chronic) inflammation 
cases can be distinguished in order to investigate and compare characteristic signatures of inflammation between 
such cases.
conclusions
Elevated levels of circulating bacterial inflammagens (specifically LPS) upregulate a variety of inflammatory bio-
markers, ultimately promoting systemic inflammation. Gut dysbiosis and ‘leaky gut’ conditions in CRC patients 
can thus contribute to their dysregulated inflammatory biomarker profile, which manifests in multiple patholog-
ical hematological changes. Importantly, systemic hypercoagulability and aberrant blood clotting are strongly 
associated with CRC status. The significant correlations observed between circulating LPS levels and TEG WB 
clot parameters, suggest that a link exists between a bacterial presence and hematological pathology. Because of 
the intricate relationship between a pathological coagulation system and chronic inflammation in the pathogene-
sis of CRC (influencing malignant growth), new therapeutic strategies targeting this bidirectional network should 
be explored66. The wider relevance of this paper lies in the identification of biomarkers of multiple groups (inflam-
matory markers, vascular damage markers, and circulating LPS), that are associated with CRC and can be used 
for screening of CRC. Blood-based inflammatory markers can be used in combination with conventional CRC 
screening approaches, and may serve as additional tools for early detection of CRC1. With the help of effective 
CRC screening with the aim of early detection, followed by early intervention, the incidence of CRC mortalities 
can be significantly reduced1,79.
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